mr JOSEPH HILL iii

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, Pharmacy and Medically Underserved Enhancement Act, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program. Support for S. 2553, Know the Lowest Price Act of 2018, which would ban "gag clauses" in contracts between Part D plans and pharmacies.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, Pharmacy and Medically Underserved Enhancement Act, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program. Support for S. 2553, Know the Lowest Price Act of 2018, which would ban "gag clauses" in contracts between Part D plans and pharmacies.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, Pharmacy and Medically Underserved Enhancement Act, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullifying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program. Support for S. 2553, Know the Lowest Price Act of 2018, which would ban "gag clauses" in contracts between Part D plans and pharmacies.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program.

Agriculture, Rural Development, Food and Drug Administration, and related Agencies Appropriations seeking Food and Drug Administration funding. Discussion with the House and Senate on opioid addiction. Support for S. 2554, Patient Right to Know Drug Prices Act, which would ban "gag clauses" in contracts between all insurers and pharmacies. Support for H.R. 6, SUPPORT for Patients and Communities Act, a bill that addresses opioid addiction.

Agriculture, Rural Development, Food and Drug Administration, and related Agencies Appropriations seeking Food and Drug Administration funding. Discussion with the House and Senate on opioid addiction. Support for S. 2554, Patient Right to Know Drug Prices Act, which would ban "gag clauses" in contracts between all insurers and pharmacies. Support for H.R. 6, SUPPORT for Patients and Communities Act, a bill that addresses opioid addiction.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with Congress on compounding. Communicated with House and Senate offices on drug shortages. Communication with DEA on opioid shortage of generic injectables. Support for S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2018, and H.R. 6142, Reducing Drug Waste Act of 2018.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with Congress on compounding. Communicated with House and Senate offices on drug shortages.Communication with DEA on opioid shortage of generic injectables. Support for S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2018, and H.R. 6142, Reducing Drug Waste Act of 2018.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, Pharmacy and Medically Underserved Enhancement Act, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program. Support for S. 2553, Know the Lowest Price Act of 2018, which would ban "gag clauses" in contracts between Part D plans and pharmacies.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, Pharmacy and Medically Underserved Enhancement Act, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullifying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program. Support for S. 2553, Know the Lowest Price Act of 2018, which would ban "gag clauses" in contracts between Part D plans and pharmacies.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, Pharmacy and Medically Underserved Enhancement Act, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullifying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program. Support for S. 2553, Know the Lowest Price Act of 2018, which would ban "gag clauses" in contracts between Part D plans and pharmacies.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PBM transparency. Support for H.R. 592/S. 109, Pharmacy and Medically Underserved Enhancement Act, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 4392, nullfying a rule finalized by the Centers for Medicare & Medicaid Services that modifies payment under Medicare for certain drugs purchased through the 340B discount program. Support for S. 2553, Know the Lowest Price Act of 2018, which would ban "gag clauses" in contracts between Part D plans and pharmacies.

Agriculture, Rural Development, Food and Drug Administration, and related Agencies Appropriations seeking Food and Drug Administration funding. Discussion with the House and Senate on opioid addiction. Support for S. 2554, Patient Right to Know Drug Prices Act, which would ban "gag clauses" in contracts between all insurers and pharmacies. Support for H.R. 6, SUPPORT for Patients and Communities Act, a bill that addresses opioid addiction.

Agriculture, Rural Development, Food and Drug Administration, and related Agencies Appropriations seeking Food and Drug Administration funding. Discussion with the House and Senate on opioid addiction. Support for S. 2554, Patient Right to Know Drug Prices Act, which would ban "gag clauses" in contracts between all insurers and pharmacies. Support for H.R. 6, SUPPORT for Patients and Communities Act, a bill that addresses opioid addiction.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with Congress on compounding. Communicated with House and Senate offices on drug shortages. Communication with DEA on opioid shortage of generic injectables. Support for S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2018, and H.R. 6142, Reducing Drug Waste Act of 2018.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with Congress on compounding. Communicated with House and Senate offices on drug shortages.Communication with DEA on opioid shortage of generic injectables. Support for S. 974, Creating and Restoring Equal Access to Equivalent Samples Act of 2018, and H.R. 6142, Reducing Drug Waste Act of 2018.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program. Letter to Senate leadership regarding H.R. 1628, American Health Care Act of 2017.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program. Letter to Senate leadership regarding H.R. 1628, American Health Care Act of 2017.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion; communication on maintaining the 340B program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion; communication on maintaining the 340B program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion; communication on maintaining the 340B program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion; communication on maintaining the 340B program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion; communication on maintaining the 340B program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion; communication on maintaining the 340B program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, MIPS/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion; communication on maintaining the 340B program.

Communication with Center for Medicare and Medicaid Services regarding Innovation Center, direct reimbursement under Medicare Program, annual payment updates, and PMB transparency. Support for H.R. 592/S. 109, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about increased prescription drug pricing. Communication on Direct and Indirect Remuneration fees (DIR) under Medicare Part D. Support for H.R. 2122/S. 974, a bill that would promote competition by limiting a manufacturers ability to prevent potential competitors from entering the market. Support for behavioral health funding and service expansion; communication on maintaining the 340B program.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opiod addiction. Discussion with Senate on antibiotic resistance.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act. Discussion with House and Senate on 21st Century Cures Act H.R. 34.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act. Discussion with House and Senate on 21st Century Cures Act H.R. 34.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act. Discussion with House and Senate on 21st Century Cures Act H.R. 34.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Support for S. 524, Comprehensive Addiction and Recovery Act. Discussion with the House on increasing prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding JW modifier, discussion with House and CMS regarding Part B payment demonstration.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opiod addiction. Discussion with Senate on antibiotic resistance.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Support with House offices on H.R. 5813 Overtime Reform and Enhancement Act. Discussion with House and Senate on 21st Century Cures Act H.R. 34.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding. Communication with the Department of Labor Defining and Delimiting the Exemptions for Executive, Administrative, Professional, Outside Sales and Computer Employees. Discussion with the House on opioid addiction. Discussion with Senate on antibiotic resistance.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Support for S. 524, Comprehensive Addiction and Recovery Act. Discussion with the House on increasing prescription drug pricing.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding Part B payment demonstration.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, MIPSA/MACRA proposal and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Discussion with House and Senate about recent FDA guidance on compounding and increasing prescription drug pricing.Communication with CMS regarding JW modifier, discussion with House and CMS regarding Part B payment demonstration.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Discussion with Senate on Chronic Condition legislation. Support for S. 524, Comprehensive Addiction and Recovery Act. Discussion with the House on increasing prescription drug pricing.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act, and Section 11 of S. 2700, FDA and NIH Workforce Authorities Modernization Act. Contact concerning the Drug Quality and Security Act, all titles. Communication with the FDA on Generic Drug User Fee Act, Prescription Drug User Fee Act, Biosimilar User Fee Act, and electronic drug information. Expressed support for S. 524, Comprehensive Addiction and Recovery Act of 2016.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Signed on to letter in support of H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Signed on to letter in support of H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Signed on to letter in support of H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

S. 1800/H.R. 3049 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2016 seeking Food and Drug Administration funding.

Communication with Center for Medicare and Medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures. Discussion with Senate on Chronic Condition legislation. Support for HR 3648, Gluten in Medicine Disclosure Act of 2015.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Signed on to letter in support of H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015. Support for H.R. 6, 21st Century Cures.

Communication with Center for Medicare and medicaid Services regarding Innovation center, direct reimbursement under Medicare Program, annual payment updates, and Part D formulary issues. Support for H.R. 592/S. 314, legislation that would amend title 18 of the Social Security Act to provide for coverage of pharmacist services under the Medicare Program. Support for H.R. 6, 21st Century Cures.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the OIG on Compendia . Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTC on biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance Patient Treatment Act.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on the labeling of generic medications and biosimilars. Communication with FTC on biosimilars.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the GAO on compounding. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTCon biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance patient Treatment Act.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the OIG on Compendia . Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTC on biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance Patient Treatment Act.

Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Contact concerning HRSA oversight of 340B drug discount program. Communication with the GAO on compounding. Contact concerning the Drug Quality and Security Act, H.R. 3204, all titles. Communication with the FDA on labeling of generic medications and drugs containing salts. Communication with FTCon biosimilars. Support for H.R. 3742, all titles, theAntibiotic Development to Advance patient Treatment Act.